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Abstract
Little is known regarding the prevalence and distribution of hepatitis B virus (HBV) infection in 
United States (US) Hispanics/Latinos. We sought to determine the prevalence of HBV exposure 
(anti-HBc), active HBV infection (HBsAg), and vaccine-induced HBV immunity (anti-HBs) in 
US Hispanics/Latinos and consider how these data inform clinical screening recommendations. 
Our analysis included 11,999 women and men of the Hispanic Community Health Study/Study of 
Latinos (HCHS/SOL), a population-based, cross-sectional household survey in four urban 
communities (Bronx, NY; Miami, FL; Chicago, IL; and San Diego, CA) of US civilian, non-
institutionalized self-identifying Hispanic/Latino adults age 18–74. Vaccine-induced immunity 
was defined as detection of anti-HBs but not anti-HBc. However, if anti-HBc were present it was 
considered evidence of exposure to HBV, with detection of HBsAg used to distinguish those with 
active HBV infection. The mean age was 45.7 years and 7,153 were women. Vaccine-induced 
immunity was greatest among those aged 18–29 years (60.2% in women, 54% in men) and 
decreased with increasing age, regardless of country of birth. The prevalence of active HBV 
infection was 0.29% (95% CI: 0.19–0.43%), but varied by country of birth. Those born in the 
Dominican Republic had the highest prevalence of HBV exposure (20.3% in women, 29.7% in 
men) and active HBV infection (0.95%).
Conclusions—The overall age-standardized prevalence of active HBV infection in Hispanic/
Latino adults (0.29%) was no different to the general US population estimate (0.27%) and did not 
exceed 2%, regardless of country of birth. These data do not support targeting HBV screening to 
US Hispanic/Latino adults based upon background.
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Hepatitis B virus (HBV) is a global public health concern with over 240 million people 
chronically infected worldwide, (1) including 730,000 non-institutionalized adults in the 
United States (US) (2). Prevalence of active HBV in the US general population estimated by 
the National Health and Nutrition Examination Survey (NHANES) 1999–2008 was 0.27% 
and was substantially higher in Non-Hispanic blacks and in persons born outside the US, 
highlighting the relevance of nativity and ethnicity in the epidemiology of HBV (3). As a 
part of efforts to curb HBV-associated morbidity and mortality, the US Centers for Disease 
Control and Prevention (CDC) released a report entitled “Recommendations for 
Identification and Public Health Management of Persons with Chronic Hepatitis B Virus 
Infection” in 2008 (3). It recommended routine HBV testing for persons born in geographic 
regions with HBV surface antigen (HBsAg) prevalence of ≥2% (3). Additionally, persons 
who report risk factors for HBV infection should be vaccinated if they test negative for HBV 
(4–7).
Persons of Latin American heritage represent the largest minority group, and are represented 
in the largest foreign born communities in the US. US Hispanic/Latinos may originate from 
regions of low (HBsAg prevalence < 2%), intermediate (2–8%) or high HBV endemicity 
(>8%) and therefore under current clinical guidelines may be subject to screening depending 
upon their country of birth (3). However, it has been acknowledged that these 
recommendations are based on limited data that may not reflect the current prevalence 
among foreign born individuals by country of birth (1, 6). Furthermore, data on HBV 
epidemiology age and birth cohorts of the US are scarce. Past studies had relatively small 
sample size and combined persons of disparate Hispanic/Latino backgrounds into a single 
group which ignores many factors of heterogeneity including heterogeneity by country of 
birth (8). Without accurate and detailed information on the prevalence of HBV infection, it 
is unclear whether the current guidelines for prevention and control of HBV infection apply 
to this heterogeneous population or meet their specific needs.
Therefore, we assessed the prevalence of HBV exposure, active HBV infection, as well as 
vaccine-induced HBV immunity in the Hispanic Community Health Study/Study of Latinos 
(HCHS/SOL); a large contemporary and representative sample of US Hispanic/Latino adults 
of diverse heritage and generational status in four US communities. We sought to consider 
whether current clinical practice recommendations about hepatitis B screening and 
vaccination reflect an accurate understanding of the distribution of HBV in US Hispanic/
Latino immigrants.
Methods
Design, Setting and Participants
The HCHS/SOL is a community-based cohort study of 16,415 Hispanic/Latino adults aged 
18–74 years from four urban US communities (Bronx, NY; Miami, FL; Chicago, IL; and 
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San Diego, CA). Its main goals are to describe chronic disease burden and to quantify all-
cause mortality in US Hispanic/Latino adults. Detailed methods and sampling design have 
been published elsewhere (9, 10). Participants were selected through a multi-stage 
probability sample designed to oversample the largest Hispanic/Latino background groups 
living in the US today (Dominicans, Central Americans, Cubans, Puerto Ricans, and South 
Americans), and persons aged 45–74 years. Participants completed a comprehensive 
baseline examination in 2008–2011 that included detailed questionnaires as well as clinical 
and behavioral examinations. Informed consent was obtained from all participants and the 
study was approved by the institutional review boards at each participating institution.
Of the 16,415 persons enrolled in the HCHS/SOL, 4,416 (26.9%) were excluded in the 
present analyses, including, 4,196 participants who were enrolled before the appropriate 
informed consent incorporating hepatitis testing was introduced into the study, 213 who 
refused to consent for hepatitis testing, 1 person who had indeterminate laboratory values, 
and 6 who were outside the sampling age range of 18–74. Overall, 11,999 (73.1%) 
participants were included in the analytic sample and their characteristics did not 
significantly differ by sex or education from the excluded subjects. However, those excluded 
were more likely to be older and varied slightly by Hispanic/Latino background (Appendix 
Table 1).
Laboratory Methods
HCHS/SOL serum specimens from the baseline examination were processed within 2 hours 
of collection, transported to a central lab and stored at −70° C. Serum specimens were tested 
for antibodies against hepatitis B surface antigen (anti-HBs) and core antibody (anti-HBc) 
and, if anti-HBc was positive, for hepatitis B surface antigen (HBsAg). Measurement of 
anti-HBs, HBsAg and anti-HBc was conducted using an ADVIA Centaur System (Siemens 
Healthcare Diagnostics, Deerfield, IL) at the HCHS/SOL Central Laboratory at the 
University of Minnesota Fairview Hospital Clinical Laboratory, Minneapolis, MN. The 
ADVIA system uses direct chemiluminometric technology for assessment of anti-HBs and 
HBsAg while anti-HBc is assessed using a sandwich immunoassay.
Data on HCV infection were also available for analyses (11). Lab methods described 
previously (11).
Outcome definitions
We defined the presence of vaccine-induced immunity when anti-HBs was positive and anti-
HBc was negative. We defined a subject as HBV exposed (with past or active infection) 
when anti-HBc was positive. Active HBV infection was defined if a person was positive for 
HBsAg.
Other Measurements
In this report, we analyzed HBV prevalence by key demographic variables that were 
obtained at the baseline interview: self-reported age (categorized in 18–29, 30–39, 40–49, 
50–59, 60–69, and 70–74 age groups), sex, place of birth (US [within the 50 US states, 
excluding territories], Dominican Republic, Central America, Cuba, Mexico, Puerto Rico, 
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and South America), and education (less than high school, high school equivalent, or greater 
than high school). Persons born in the US, regardless of Hispanic/Latino background, were 
considered as a single group as they would have been exposed to the same vaccination 
policies as the general population. While residents of Puerto Rico are US citizens by birth, 
for the purposes of this manuscript we considered Puerto Ricans born in the island 
separately from those born stateside.
Statistical Analysis
All statistical analyses accounted for study probability sampling design and non-response 
with appropriate sampling weights, and were completed with SAS-callable SUDAAN 11.0 
(Research Triangle Institute, Research Triangle Park, NC). Weighted results are 
representative of non-institutionalized Hispanic/Latino adults age 18–74 years of age in the 
defined community areas. To allow comparability between HBV prevalence in HCHS/SOL 
with those from those of other studies, prevalence estimates were age-standardized to the 
2010 US Census in ten-year age groups (18–29, 30–39, 40–49, 50–59, 60–69, and 70–74) 
using the Descript procedure (12). We examined age-standardized prevalence of (1) vaccine 
induced HBV immunity, (2) exposure to HBV, and (3) active HBV infection by key 
demographic characteristics (nativity and Hispanic/Latino background, exposure to HCV, 
and education level). Data were stratified by gender, except for the prevalence of active 
infection, where the number of cases was small (n=36). To assess birth cohort trends, 
prevalence of vaccine-induced immunity and exposure to HBV infection were also assessed 




The mean age of the analytic cohort was 45.7 years (SD=13.9) and 7,153 (59.2%) were 
women. The number that were US born and foreign-born by Hispanic/Latino background 
were as follows: Dominican [n=103 (0.9%) and n=1024 (8.5%)], Central American [n=60 
(0.5%), n=1191 (9.9%)], Cuban [n=90 (0.8%), n=1857 (15.5%)], Mexican [n=772 (6.4%), 
n=3903 (32.5%)], Puerto Rican [n=759 (6.3%), n=1068 (8.9%)], South American [n=37 
(0.3%), n=747 (6.2%)], and mixed/other background [n=207 (1.7%), n=136 (1.1%)]. The 
majority of the participants preferred to be interviewed in Spanish [n=9,700 (90.8%)] and 
were foreign-born [n=9,931 (92.8%)].
Prevalence of vaccine-induced immunity
Among women, 25.0% (95% CI: 23.6–26.5) had vaccine-induced immunity as compared 
with 21.0% (95% CI: 20.0–22.6) of men (Table 1). In both women and men, vaccine-
induced immunity prevalence was the highest among younger age group of 18–29 years 
(60.2% and 53.7% respectively) and decreased with age. The prevalence of vaccine-induced 
immunity were 26.0% (95% CI: 23.3–28.9) in US born women and 27.2% (95% CI: 23.8–
30.9) in US born men. Among the US born, the prevalence were similar among different 
Hispanic/Latino background groups (data not shown). However, among foreign-born 
Hispanics, prevalence of vaccine-induced immunity varied by Hispanic/Latino background. 
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Those born in Cuba had the highest prevalence of vaccine-induced immunity in both women 
and men (39.5% and 34.3%, respectively), while those born in Central America and Mexico 
had the lowest. Those having less than high school education had the lowest vaccine-
induced immunity prevalence.
To examine time trend in HBV vaccination, we examined prevalence of vaccine-induced 
immunity by decade of birth among the US born and the foreign-born Hispanics/Latinos by 
their place of birth (Figure 1). The general pattern is that the prevalence of vaccine-induced 
immunity increased progressively with each birth decade, and the highest prevalence was 
among those born in or after 1990. Among participants born in 1990 or after, US born 
participants and foreign-born Cubans had the highest vaccine-induced immunity rate of 
76.8% and 78.9%, respectively, and foreign-born Mexicans had the lowest of 40.3%. 
Among those born between 1980 and 1989, even greater disparity was observed in the 
prevalence of vaccine-induced immunity between the US born (nearly 60% prevalent) and 
those with other countries of birth. In general, there was an inverse association between 
vaccine-induced immunity and HBV exposure in US born and foreign-born Hispanic/Latino 
adults. These results are suggestive rather than conclusive due to limited sample size in 
some subgroups.
Prevalence of exposure to HBV
Serological evidence consistent with exposure to HBV was statistically significantly higher 
in men than in women (10.0% versus 6.4%, P < 0.0001, Table 1). The gender-difference 
was statistically significant (P < 0.05) in foreign-born Hispanic/Latino adults but not in 
those born in the US. Prevalence of exposure to HBV increased with age and the peak 
prevalence was in persons 70–74 years old in both women and men. Among all groups 
defined by birthplace, foreign-born Dominicans had the highest prevalence (20.3% in 
women and 29.7% in men). Those born in Puerto Rico had the greatest gender difference in 
HBV exposure (6.5% among women and 18.3% among men, P < 0.0001). Prevalence of 
HBV among those ever infected with HCV was high, exceeding 40% among women and 
50% among men. The prevalence of exposure to HBV varied profoundly by decade of birth 
(Figure 1). Over time, prevalence of exposure to HBV within birth cohorts decreased as the 
prevalence of vaccine induced immunity increased. In US born participants, the greatest 
prevalence of HBV exposure (16.8%) was observed in persons born between 1950–1959. 
Among Mexico-born and Puerto Rico-born individuals, the peak HBV exposure was in 
persons born between 1950–1959. In contrast, those born in the Dominican Republic, 
Central America, and South America all had peak prevalence of HBV exposure among 
persons born between 1933–1939. Prevalence of HBV exposure in subsequent decades was 
lower.
Prevalence of active HBV infection
Overall prevalence of active HBV infection was 0.29% (95% CI: 0.19% to 0.43%). Men 
were marginally more likely than women to have active HBV infection (0.43% vs 0.16%, P 
= 0.03, Table 2). Prevalence was the highest among individuals aged 40 years and older. 
Among those who were foreign-born, the highest prevalence of active HBV infection was 
among those born in Dominican Republic (0.95%, 95% CI: 0.48% to 1.86%). Those with 
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HCV exposure did not have a higher prevalence of active HBV infection than those who did 
not, and the prevalence of active HBV infection decreased with increasing level of 
education, though these differences did not reach statistical significance.
DISCUSSION
We report the first large-scale population-based data on HBV infection among US Hispanic/
Latino adults by place of birth. Overall prevalence was 22.3% for vaccine-induced immunity 
to HBV, 7.7% for exposure to HBV, and 0.29% for active HBV infection. For US born 
Hispanics/Latinos, age-standardized prevalence of active HBV infection was (0.57%) and as 
expected, vaccine-induced immunity was more common in the youngest age groups. Among 
foreign-born Hispanics/Latinos, our best estimate of the prevalence of active HBV infection 
did not exceed 2% in any group defined by their place of birth, regardless of Latin American 
background. Those born in the Dominican Republic had the highest prevalence of any group 
defined by birthplace, 0.95%, with an upper 95% confidence limit of 1.86%. Confidence 
intervals for all prevalence estimates were relatively wide due to the rarity of active HBV 
infection. However, our study, which is one of the only large studies to estimate HBV 
prevalence among Latin American migrants to the US, suggests that the approach of 
targeting clinical HBV screening to US Hispanic/Latino adults based upon country of birth 
has relativity weak ability to identify groups at high risk of HBV infection. Identification of 
groups at high risk of HBV infection by national background among Hispanics/Latinos is 
likely to be a relatively inefficient public health approach, as compared with targeting those 
who have individual risk factors for HBV infection or when are in close contact with an 
HBV infected person.
The striking differences in the prevalence of HBV vaccine-induced immunity by decade of 
birth were expected and are likely due to the different implementation of universal HBV 
vaccination for infants in the Americas (13). Within each birth cohort, the variation in 
vaccine-induced immunity by place of birth may reflect the different years HBV infant 
vaccination was introduced in each country. Data among US born Hispanics/Latinos are 
compatible with the introduction of an infant immunization strategy to eliminate 
transmission of HBV infection in 1991. The proportion of US born Hispanic/Latino adults 
vaccinated against HBV has risen among successive birth cohorts, reaching 76.8% among 
Hispanics/Latinos born in the US after 1990, and these data are consistent with trends in the 
general US population (8). Vaccination coverage in our study is above that reported by 
NHANES, however, these figures are below the 95% target of children in kindergarten (14) 
highlighting the need to improve universal childhood vaccination coverage. Indeed, 
disparities in vaccination coverage by socio-economic status and race/ethnicity have been 
well-documented for other vaccine-preventable diseases (15, 16). Overall, the prevalence of 
vaccine-induced immunity was significantly higher in women compared to men. Among 
foreign-born Hispanic/Latino adults, the prevalence of vaccine induced immunity tended to 
be higher in women as compared to men, though differences were only statistically 
significant for Mexicans born individuals. These gender differences may be attributed to 
antenatal testing in women and different health seeking behavior between men and women 
(17, 18).
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The heterogeneity of past HBV exposure by place and decade of birth is consistent with the 
local epidemiology of HBV infection and with HBV vaccination programs in countries of 
birth (1, 7). By studying adults from various Latin American backgrounds over a wide range 
of age from 18 to 74 years old, we were able to document that differences in the 
epidemiology of HBV by place of birth are most pronounced among oldest persons and are 
decreasing across subsequent generations. Those born in the Dominican Republic, 
particularly the men, had a significantly higher prevalence of HBV exposure than those born 
in other regions.
For all the Hispanics/Latinos adults in HCHS/SOL, age-standardized prevalence of active 
HBV infection was 0.29%, which is comparable to the 0.28% national estimate from 
NHANES 1999–2008 (8). There were substantial differences by Latin American country of 
origin, though the best estimate of the prevalence of active HBV infection was below 2% for 
all places of birth. However, it is important to note that while the HCHS/SOL includes a 
diverse sample of the largest Hispanic/Latino background groups in the US, it does not take 
into account potential regional variation within nation of birth. For example, we do not 
distinguish persons from the Amazonian basin from those from urban areas of South 
America. Moreover, due in part to small numbers of active HBV infections, confidence 
intervals associated with prevalence estimates were wide, pointing to a need to additional 
data to refine the true prevalences of active HBV infection among immigrants from Latin 
America.
Though we do not have data on risk factors for HBV infection, several observations suggest 
that most of the HBV transmission in the Hispanic/Latino community in the US was likely 
to have taken place outside of childhood. First, the excess of ever HBV infected individuals 
over actively infected individuals is large, and it is well known that clearance of HBV is 
more common when infections are acquired in adulthood (19). Second, significantly higher 
prevalence of past exposure to HBV in men as compared with women is consistent with 
transmission during adolescence and adulthood as these well documented gender differences 
may be attributed to the higher frequency of risky behaviors, such as intravenous drug-use 
and having multiple sexual partners, in men (8). Finally, persons with positive HCV 
serology were significantly more likely to have been exposed to HBV than those without, an 
expected finding given both viruses share transmission routes such as unsafe blood 
transfusion and injection equipment (20). While current guidelines recommend HBV 
vaccination for patients with HCV infection, our data identifies missed opportunities for 
HBV vaccination in the HCV infected population which may be explained by a lack of 
awareness of HCV serostatus (11). We cannot infer from our data, though, if HBV infection 
or vaccination took place before or after migration into the US.
There are several limitations to the present study. The HCHS/SOL population was sampled 
in four urban areas of the US with concentrated Hispanic/Latino populations, and 
incarcerated or homeless persons were not included in our study sample which may lead to 
an underestimate of the true HBV infection prevalence. We used a household based 
sampling approach, albeit we did not assess the HBV status of all members at each 
household. Hispanics/Latinos in other regions of the US, such as New Mexico, Texas, and 
Arizona, are not included in our analysis.
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These regions have a predominance of immigrants from Mexico which is a country known 
to have low prevalence of HBV exposure (21). Mexican immigrants living in several other 
US regions were captured in our survey. The present study is underpowered to provide HBV 
prevalence estimates for some Hispanic/Latino background groups that were not adequately 
captured in our survey. Strengths include the large sample size with standardized methods 
for specimen collection and testing, and population-based sampling which allows for 
weighted prevalence estimates by place of birth.
Our findings have important clinical and public health policy implications. With the 
exception of migrants from the Dominican Republic, the prevalence of active HBV infection 
of foreign-born Hispanic/Latinos may not be different than that among the general US 
population. In all populations, including the Dominican Republic group, our best estimate of 
the prevalence of active HBV infection falls below the 2% threshold, which is the criterion 
for defining high prevalence in the current HBV screening recommendations. Our findings 
are timely and provide an answer to the call issued by USPSTF for tools to help clinicians 
efficiently and accurately identify populations at high risk for HBV infection. Given the 
apparently low prevalence of active HBV infection in all groups studied here, applying HBV 
screening in certain groups of Hispanics/Latinos in the US as defined by place of birth may 
not be an efficient strategy. Since confidence intervals for prevalence estimates were wide, 
our study highlights the need for more data to refine our understanding of populations at 
risk. Instead, efforts should be focused to reach those Hispanic/Latinos at risk for HBV 
infection based on established behavioral risk factors, and to maximize compliance with 
childhood vaccination recommendations. Finally, cost-effectiveness analysis (19) might be 
applied to develop the best HBV testing and adult vaccination approaches in the US Latino 
population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial support information:
The Hispanic Community Health Study/Study of Latinos was carried out as a collaborative study supported by 
contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (N01-
HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), 
Northwestern University (N01-HC65236), and San Diego State University (N01-HC65237). The following 
Institutes/Centers/Offices contribute to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute 
on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, 
National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements.
Dr. de Amo was supported by grant BA14CIII/00003 from the Fondo de Investigacions Sanitarias (BAE).
Abbreviations
HBV Hepatitis B virus
HBsAg serum HBV surface antigen
Jung et al. Page 8













anti-HBs antibody against HBV surface antigen
anti-HBc serum HBV core antibody
US United States
HCHS/SOL Hispanic Community Health Study/Study of Latinos
NHANES National Health and Nutrition Examination Survey
References
1. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new 
estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12):2212–9. 
[PubMed: 22273662] 
2. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence 
of hepatitis B virus infection in the United States in the era of vaccination. Journal of Infectious 
Diseases. 2010; 202(2):192–201. [PubMed: 20533878] 
3. Weinbaum, CM.; Williams, I.; Mast, EE.; Wang, SA.; Finelli, L.; Wasley, A., et al. Morbidity and 
Mortality Weekly Report (MMWR). Department of Health and Human Services, Public Health 
Service, Centers for Disease Control and Prevention; 2008. Recommendations for identification and 
public health management of persons with chronic hepatitis B virus infection; p. 1-20.
4. Mast, EE.; Margolis, HS.; Fiore, AE.; Brink, EW.; Goldstein, ST.; Wang, SA., et al. Morbidity and 
Mortality Weekly Report (MMWR). Department of Health and Human Services, Public Health 
Service, Centers for Disease Control and Prevention; 2005. A comprehensive immunization strategy 
to eliminate transmission of hepatitis B virus infection in the United States; p. 1-32.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661–2. 
[PubMed: 19714720] 
6. LeFevre ML. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: US 
Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2014; 
161(1):58–66. [PubMed: 24863637] 
7. Komatsu H. Hepatitis B virus: Where do we stand and what is the next step for eradication? World 
Journal of Gastroenterology. 2014; 20(27):8998–9016. [PubMed: 25083074] 
8. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a 
nationally representative survey. Annals of Internal Medicine. 2011; 154(5):319–28. [PubMed: 
21357909] 
9. Sorlie PD, Avilés-Santa LM, Wassertheil-Smoller S, Kaplan RC, Daviglus ML, Giachello AL, et al. 
Design and Implementation of the Hispanic Community Health Study/Study of Latinos. Annals of 
Epidemiology. 2010; 20(8):629–41. [PubMed: 20609343] 
10. LaVange LM, Kalsbeek WD, Sorlie PD, Avilés-Santa LM, Kaplan RC, Barnhart J, et al. Sample 
design and cohort selection in the Hispanic Community Health Study/Study of Latinos. Annals of 
Epidemiology. 2010; 20(8):642–9. [PubMed: 20609344] 
11. Kuniholm MH, Jung M, Everhart JE, Cotler S, Heiss G, McQuillan G, et al. Prevalence of 
Hepatitis C Virus Infection in US Hispanic/Latino Adults: Results from the NHANES 2007–2010 
and HCHS/SOL Studies. Journal of Infectious Diseases. 2014; 209(10):1585–90. [PubMed: 
24423693] 
12. U.S. Census Bureau. 2010 Census Briefs. 2010. Age and Sex Composition: 2010. 
13. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). 
Department of Health and Human Services, Public Health Service, Centers for Disease Control 
and Prevention; 1990. Protection Against Viral Hepatitis Recommendations of the Immunization 
Practices Advisory Committee (ACIP); p. 1-26.
14. US Department of Health and Human Services. Healthy People 2020. Immunization and Infectious 
Diseases. 
Jung et al. Page 9













15. Klevens RM, Luman ET. US children living in and near poverty: risk of vaccine-preventable 
diseases. American journal of preventive medicine. 2001; 20(4):41–6. [PubMed: 11331131] 
16. Wood D, Donald-Sherbourne C, Halfon N, Tucker MB, Ortiz V, Hamlin JS, et al. Factors related 
to immunization status among inner-city Latino and African-American preschoolers. Pediatrics. 
1995; 96(2):295–301. [PubMed: 7630688] 
17. Force UPST. Screening for hepatitis B virus infection in pregnancy: US Preventive Services Task 
Force reaffirmation recommendation statement. Annals of internal medicine. 2009; 150(12):869. 
[PubMed: 19528565] 
18. Waldron I. Sex differences in illness incidence, prognosis and mortality: issues and evidence. 
Social science & medicine. 1983; 17(16):1107–23. [PubMed: 6623118] 
19. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clinical 
Infectious Diseases. 1995; 20(4):992–1000. [PubMed: 7795104] 
20. Alter MJ. Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology. 2007; 
13(17):2436. [PubMed: 17552026] 
21. Pew Research Center. Pew Research Center. Mapping the Latino Poulation, by State, Country and 
City. 2013. 
Jung et al. Page 10














Jung et al. Page 11


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Jung et al. Page 14
Table 2
Age-standardized prevalence of active Hepatitis B virus infection in US Hispanic adults, HCHS/SOL 2008–
2011*
Overall Active Infection
Subgroup N Prevalence % (95% CI)
Overall 11,999 0.29 (0.19, 0.43)
Age Group†
 18–29 1,961 0.16 (0.05, 0.47)
 30–39 1,798 0.14 (0.04, 0.42)
 40–49 3,116 0.49 (0.24, 1.00)
 50–59 3,134 0.39 (0.21, 0.72)
 60–69 1,637 0.38 (0.10, 1.37)
 70–74 353 0
Sex
 Women 7,153 0.16 (0.09, 0.29)
 Men 4,846 0.43 (0.26, 0.72)
Place of Birth
 US born – Overall 2,028 0.57 (0.09, 3.48)
 Foreign-born Dominican Republic 1,024 0.95 (0.48, 1.86)
 Foreign-born Central America 1,191 0.13 (0.04, 0.40)
 Foreign-born Cuba 1,857 0.39 (0.16, 0.95)
 Foreign-born Mexico 3,903 0.14 (0.06, 0.31)
 Foreign-born Puerto Rico 1,068 0.12 (0.03, 0.50)
 Foreign-born South America 747 0.62 (0.15, 2.50)
HCV
 Ever exposed 260 0.18 (0.02, 1.26)
 Never exposed 11,703 0.29 (0.19, 0.44)
Education
 Less than high school 4,423 0.46 (0.25, 0.84)
 High school graduate or equivalent 3,037 0.26 (0.13, 0.56)
 More than high school 4,270 0.15 (0.06, 0.37)
Abbreviations: HCHS/SOL = Hispanic Community Health Study/Study of Latinos; HBV = hepatitis B virus; US = United States; HCV = Hepatitis 
C virus.
*
All values (prevalence and 95% CI), except subgroup n, are weighted to account for survey design. Prevalence and 95% CI are age-standardized 
to 2010 US Census.
†
Not age-standardized.
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